Investment
Features
FeesSafety
Academy
More
Pluang+

BBDC upgraded to buy with strong dividends, stable NAV, and 14% upside potential.

Analyst Insights
27 Sep 2026
Seeking Alpha
View Source
Bullish
BBDC upgraded to buy with strong dividends, stable NAV, and 14% upside potential.

Barings BDC (BBDC) has been upgraded to a buy rating due to its strong financial health, including robust dividend coverage at 108%, a stable net asset value with only a 2.1% annual decline, and low non-accruals under 1%. The stock offers a sustainable 12% yield supported by durable net interest income and additional spillover income. Trading at a 20% discount to book value, Wall Street analysts see a potential 14% upside, suggesting double-digit total return potential for investors. This upgrade reflects BBDC's resilience compared to its business development company peers and its ability to outperform expectations.

Barings BDC's recent rating upgrade comes amid a Financials sector where 57 of 85 US stocks traded on Pluang rose as of Sep 27, 2026 17:21 WIB. For readers following this sector, here is Pluang's market snapshot: PayPal Holdings, Inc. (PYPL) gained 4.64% to USD 55.04 with a typical hold time of 106 days and a Pluang order activity split of 55% Sell / 45% Buy, contrasting with Hut 8 Corp (HUT) which fell 4.65% to USD 96.82 and saw 96% Buy orders over 11 days. TeraWulf Inc (WULF) also declined 3.38% to USD 15.74 but had 100% Buy orders over 16 days.

More News

Zcash (ZEC) price drops 2% in an hour amid $700K long liquidations on major exchanges

Zcash (ZEC) price drops 2% in an hour amid $700K long liquidations on major exchanges

Zcash (ZEC) experienced a 2.01% price drop within an hour on September 27, falling from $1,650 to $1,617 on Binance's spot market. Despite this decline, ZEC remains up nearly 5% over the past 24 hours. During the same hour, long liquidations totaled ...

Market News
Bearish
4 hours ago
United Therapeutics rated Buy despite revenue dips; key growth from Tyvaso DPI and upcoming FDA reviews.

United Therapeutics rated Buy despite revenue dips; key growth from Tyvaso DPI and upcoming FDA reviews.

United Therapeutics is rated Buy with a base valuation of $535 per share, despite recent revenue declines caused by competition from Liquidia's Yutrepia. The company's main growth driver remains Tyvaso DPI, with declines limited to older drug formula...

Analyst Insights
Bullish
4 hours ago
Ethereum plans quantum-safe, scalable upgrades by 2030 with advanced proof-of-stake and zero-knowledge proofs.

Ethereum plans quantum-safe, scalable upgrades by 2030 with advanced proof-of-stake and zero-knowledge proofs.

Ethereum co-founder Vitalik Buterin outlined a vision for the network by 2030 to become a cryptographic computing system with enhanced security and scalability. The plan includes using PeerDAS data sampling and SNARK verification to reduce node workl...

Protocol Fundamentals
Bullish
4 hours ago
GoDaddy shares rise as Gen Digital's takeover bid report causes its stock to plunge

GoDaddy shares rise as Gen Digital's takeover bid report causes its stock to plunge

Shares of Gen Digital fell over 12% after reports of a preliminary takeover approach for GoDaddy, whose shares rose nearly 5%. The market reaction suggests skepticism about Gen Digital's ability to finance the deal, given their similar market values ...

Market News
Neutral
4 hours ago
Ethereum plans major upgrades by 2030 to boost security and scalability, but $10K price seems unlikely by 2026.

Ethereum plans major upgrades by 2030 to boost security and scalability, but $10K price seems unlikely by 2026.

Ethereum co-founder Vitalik Buterin has revealed a bold roadmap aiming for major technological upgrades by 2030, including advanced cryptography and a protocol redesign to improve scalability, privacy, and security. Despite these ambitious plans, mar...

Protocol Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App